<div id="readability-page-1"><p>Edge Capital Group LLC cut its stake in  Eli Lilly and Company (NYSE:LLY - Free Report) by 12.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor  owned 10,509 shares of the company's stock after selling 1,435 shares during the period. Edge Capital Group LLC's holdings in Eli Lilly and Company were worth $8,113,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>Biogen Stock Is Mutating Into a Value Play</li></ul><p>Several other large investors also recently bought and sold shares of the company. Pathway Financial Advisers LLC boosted its position in  Eli Lilly and Company by 92,759.9% during the third quarter. Pathway Financial Advisers LLC now owns 1,022,388 shares of the company's stock worth $905,774,000 after acquiring an additional 1,021,287 shares during the last quarter.  Integrated Investment Consultants LLC lifted its position in  Eli Lilly and Company by 37,140.7% during the 3rd quarter. Integrated Investment Consultants LLC now owns 694,167 shares of the company's stock worth $614,990,000 after acquiring an additional 692,303 shares in the last quarter.  Strategic Financial Concepts LLC lifted its position in shares of  Eli Lilly and Company by 126,531.5% during the fourth quarter. Strategic Financial Concepts LLC now owns 678,745 shares of the company's stock worth $523,991,000 after purchasing an additional 678,209 shares in the last quarter.  Mizuho Securities USA LLC boosted its position in  Eli Lilly and Company by 599.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 430,853 shares of the company's stock valued at $381,710,000 after buying an additional 369,293 shares during the last quarter.  Finally, Holocene Advisors LP boosted its holdings in  Eli Lilly and Company by 257.1% in the third quarter. Holocene Advisors LP now owns 437,603 shares of the company's stock valued at $387,690,000 after purchasing an additional 315,065 shares during the last quarter. Institutional investors and hedge funds own  82.53% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>LLY has been the subject of a number of research analyst reports. Redburn Atlantic upgraded Eli Lilly and Company to a &#34;hold&#34; rating in a report on Monday, November 4th. Berenberg Bank  set a $970.00 target price on Eli Lilly and Company in a research note on Thursday, January 16th. Barclays reduced their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an &#34;overweight&#34; rating for the company in a report on Thursday, October 31st. Leerink Partners  set a $950.00 target price on shares of Eli Lilly and Company in a research note on Friday, January 17th. Finally, Wolfe Research started coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They set an &#34;outperform&#34; rating and a $1,000.00 target price for the company. Three analysts have rated the stock with a hold rating and eighteen have issued  a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $1,000.28.</p><ul><li>Hims &amp; Hers Earnings Could Be a Game Changer—What to Do Now</li></ul><p><b>View Our Latest Stock Report on Eli Lilly and Company</b></p><h2>Eli Lilly and Company Trading Up 0.1 %</h2><p>Shares of LLY stock opened at $874.12 on Monday. The stock has a market capitalization of $828.82 billion, a PE ratio of 74.65, a P/E/G ratio of 1.40 and a beta of 0.42. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The business has a 50-day moving average of $801.33 and a 200 day moving average of $847.66. </p><ul><li>Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside</li></ul><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%.  As a group, sell-side analysts anticipate that  Eli Lilly and Company will post 23.48 earnings per share for the current year. </p><p>Eli Lilly and Company announced that its board has initiated a share buyback plan on Monday, December 9th that permits the company to buyback $15.00 billion in    shares. This buyback authorization permits the company to repurchase up to 2% of its stock  through open market purchases. Stock  buyback plans are often an indication that the company's leadership believes its stock is undervalued. </p><h2>Eli Lilly and Company Increases Dividend</h2><p>The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a yield of 0.69%. Eli Lilly and Company's payout ratio is currently 51.24%. </p><h2>Eli Lilly and Company Profile</h2> (Free Report)<p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>What Are Some of the Best Large-Cap Stocks to Buy?</li><li>5 S&amp;P 500 Dividend Stocks Set to Reward Investors</li><li>ESG Stocks, What Investors Should Know</li><li>Why Genuine Parts Company Is a Royally Good Buy Right Now</li><li>How to Find Undervalued Stocks</li><li>Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch</li></ul><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Edge Capital Group LLC reduced its stake in Eli Lilly and Company (NYSE: LLY) by 12% in Q4, now holding 10,509 shares valued at $8.11 million. Other investors, including Pathway Financial Advisers LLC and Integrated Investment Consultants LLC, significantly increased their positions. Analysts have a consensus rating of "Moderate Buy" for LLY, with a target price of $1,000.28. The stock opened at $874.12, with a market cap of $828.82 billion. Eli Lilly's recent earnings report showed $5.32 EPS, missing estimates, and the company announced a $15 billion share buyback plan.</p>

Eli Lilly and Company (NYSE:LLY) Shares Sold by Edge Capital Group LLC